Shattuck Labs (NASDAQ:STTK) Upgraded at Leerink Partnrs

Leerink Partnrs upgraded shares of Shattuck Labs (NASDAQ:STTK) to a strong-buy rating in a research report released on Monday morning,Zacks.com reports.

Separately, Leerink Partners initiated coverage on shares of Shattuck Labs in a research report on Monday. They issued an “outperform” rating and a $4.00 target price for the company. Four equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Shattuck Labs Stock Up 2.6 %

STTK stock opened at $1.19 on Monday. The firm’s 50-day simple moving average is $1.24 and its 200 day simple moving average is $1.59. The stock has a market cap of $56.81 million, a PE ratio of -0.78 and a beta of 1.66. Shattuck Labs has a fifty-two week low of $0.94 and a fifty-two week high of $11.76.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. FMR LLC lifted its position in shares of Shattuck Labs by 0.4% in the third quarter. FMR LLC now owns 7,159,090 shares of the company’s stock worth $24,985,000 after purchasing an additional 26,460 shares in the last quarter. Prosight Management LP raised its position in Shattuck Labs by 15.1% during the fourth quarter. Prosight Management LP now owns 6,638,935 shares of the company’s stock valued at $8,033,000 after acquiring an additional 873,409 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its position in Shattuck Labs by 61.2% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 4,675,000 shares of the company’s stock valued at $5,657,000 after acquiring an additional 1,775,000 shares in the last quarter. 683 Capital Management LLC bought a new position in Shattuck Labs during the fourth quarter valued at approximately $1,270,000. Finally, Geode Capital Management LLC raised its position in shares of Shattuck Labs by 0.9% in the third quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock valued at $3,184,000 after purchasing an additional 8,133 shares during the period. 58.74% of the stock is currently owned by institutional investors and hedge funds.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.